Emerging pharmacologic therapies for osteoporosis (Q36944034)

17 August 2017

1 reference

title

Emerging pharmacologic therapies for osteoporosis (English)

1 reference

17 August 2017

0 references

Andrew Grey

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

12

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

493-508

1 reference

Epidemiology and outcomes of osteoporotic fractures

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Minireview: the OPG/RANKL/RANK system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Are nonresorbing osteoclasts sources of bone anabolic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Early discontinuation of treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Non-compliance: the Achilles' heel of anti-fracture efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Osteoblast apoptosis and bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Tibolone for postmenopausal women: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

LIFT study to continue as planned

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Osteoimmunology: interplay between the immune system and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Targeting protein kinases for bone disease: discovery and development of Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Chloride channels of intracellular organelles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

21 January 2018

Nitric oxide and bone

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Parathyroid hormone as a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Mechanisms of action and therapeutic potential of strontium in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Stimulation of bone formation in vitro and in rodents by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The role of statins as potential targets for bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Leptin regulates bone formation via the sympathetic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of propranolol on bone metabolism in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Inhibition of Bone Resorption in Tissue Culture by Membrane-Stabilizing Drugs*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Use of beta-blockers and risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

LRP6 mutation in a family with early coronary disease and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

High bone mass in mice expressing a mutant LRP5 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Essential role of beta-catenin in postnatal bone acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The role of regulated CFTR trafficking in epithelial secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

MEPE has the properties of an osteoblastic phosphatonin and minhibin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.493

10.1517/14728214.12.3.493

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference